NASDAQ:LFCR Lifecore Biomedical (LFCR) Stock Price, News & Analysis $6.38 -0.03 (-0.39%) As of 03:06 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Lifecore Biomedical Stock (NASDAQ:LFCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lifecore Biomedical alerts:Sign Up Key Stats Today's Range$6.35▼$6.4050-Day Range$4.09▼$6.5952-Week Range$3.63▼$8.98Volume245,471 shsAverage Volume283,489 shsMarket Capitalization$241.65 millionP/E RatioN/ADividend YieldN/APrice Target$6.50Consensus RatingReduce Company Overview Lifecore Biomedical, Inc. is a contract development and manufacturing organization (CDMO) focused on sterile injectable pharmaceutical products. The company works with customers on product development, formulation, analytical testing, regulatory support and commercial-scale manufacturing, including fill-finish services. Lifecore also develops and manufactures hyaluronic acid, a biopolymer used in medical products and other applications. Its capabilities support products in areas such as ophthalmology and orthopedics, as well as pharmaceutical and veterinary uses. Based in Chaska, Minnesota, Lifecore serves pharmaceutical and medical technology companies in the United States and internationally. The business has a history in hyaluronic acid production and has expanded its role as a CDMO serving customers from development through commercial manufacturing.AI Generated. May Contain Errors. Read More Lifecore Biomedical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreLFCR MarketRank™: 1.09119411123 of 5 starsLifecore Biomedical scored higher than 22% of companies evaluated by MarketBeat, and ranked 1531st out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingReduce Consensus RatingLifecore Biomedical has received a consensus rating of Reduce. The company's average rating score is 1.60, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 2 sell ratings.Upside/DownsideThe consensus price target for Lifecore Biomedical is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageLifecore Biomedical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lifecore Biomedical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lifecore Biomedical are expected to grow in the coming year, from ($1.83) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lifecore Biomedical is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lifecore Biomedical is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.75% of the float of Lifecore Biomedical has been sold short.Short Interest Ratio / Days to CoverLifecore Biomedical has a short interest ratio ("days to cover") of 3.52, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lifecore Biomedical has recently decreased by 4.49%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLifecore Biomedical does not currently pay a dividend.Dividend GrowthLifecore Biomedical does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Lifecore Biomedical this week, compared to 2 articles on an average week. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lifecore Biomedical insiders have not sold or bought any company stock.Percentage Held by Insiders32.68% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lifecore Biomedical's insider trading history. Receive LFCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LFCR Stock News HeadlinesLifecore Biomedical Inc.November 12, 2026 | marketwatch.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)November 11, 2026 | globenewswire.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 19 at 1:00 AM | Profits Run (Ad)Lifecore's Q3 Loss Widens To $40 Mln As New PPQ Contract GainedNovember 5, 2026 | rttnews.comLifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate UpdateNovember 4, 2026 | markets.businessinsider.comLifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate UpdateNovember 4, 2026 | globenewswire.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)October 30, 2026 | globenewswire.comIs Lifecore Biomedical (LFCR) an Asymmetric Risk-Reward in Pharma Contract Manufacturing?October 23, 2026 | insidermonkey.comSee More Headlines LFCR Stock Analysis - Frequently Asked Questions How have LFCR shares performed this year? Lifecore Biomedical's stock was trading at $8.18 at the beginning of 2026. Since then, LFCR stock has decreased by 22.2% and is now trading at $6.3650. How were Lifecore Biomedical's earnings last quarter? Lifecore Biomedical, Inc. (NASDAQ:LFCR) released its earnings results on Wednesday, November, 4th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.78. The business had revenue of $25.32 million for the quarter, compared to analyst estimates of $25.57 million. Who are Lifecore Biomedical's major shareholders? Lifecore Biomedical's top institutional investors include State Street Corp (1.68%), Marshall Wace LLP (0.68%), Allspring Global Investments Holdings LLC (0.44%) and Tocqueville Asset Management L.P. (0.25%). Insiders that own company stock include Wynnefield Partners Small Cap and Paul Josephs. View institutional ownership trends. How do I buy shares of Lifecore Biomedical? Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/04/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 LFCR's financial health is in the Green zone, according to TradeSmith. LFCR has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:LFCR CIK1005286 Webwww.lifecore.com Phone(952) 368-4300Fax650-368-9818Employees382Year Founded1965Price Target and Rating Average Price Target for Lifecore Biomedical$6.50 High Price Target$6.50 Low Price Target$6.50 Potential Upside/Downside+2.0%Consensus RatingReduce Rating Score (0-4)1.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-56.80% Pretax MarginN/A Return on EquityN/A Return on Assets-29.53% Debt Debt-to-Equity RatioN/A Current Ratio3.84 Quick Ratio2.59 Sales & Book Value Annual Sales$128.87 million Price / Sales1.88 Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book-3.29Miscellaneous Outstanding Shares37,906,000Free Float25,518,000Market Cap$241.65 million OptionableOptionable Beta0.99 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:LFCR) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | Sponsored“IMPERIUM”: The #1 investment of 2027Could a strange new bio-chip be the most transformative innovation in history? Elon Musk calls it "amazing." A...Banyan Hill Publishing | SponsoredMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifecore Biomedical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.